The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...
Shares of Hims & Hers Health (HIMS) plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Eli Lilly’s (LLY ... option for weight loss as well as Type 2 ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results